Atria Wealth Solutions Inc. Buys 21,516 Shares of Bristol-Myers Squibb (NYSE:BMY)

Atria Wealth Solutions Inc. increased its stake in shares of Bristol-Myers Squibb (NYSE:BMY) by 12.7% during the 4th quarter, Holdings Channel.com reports. The firm owned 190,678 shares of the biopharmaceutical company’s stock after acquiring an additional 21,516 shares during the quarter. Atria Wealth Solutions Inc.’s holdings in Bristol-Myers Squibb were worth $10,785,000 at the end of the most recent reporting period.

Several other hedge funds have also modified their holdings of BMY. AMF Tjanstepension AB boosted its stake in Bristol-Myers Squibb by 6.9% in the third quarter. AMF Tjanstepension AB now owns 610,181 shares of the biopharmaceutical company’s stock valued at $31,618,000 after acquiring an additional 39,419 shares during the last quarter. Swedbank AB boosted its position in shares of Bristol-Myers Squibb by 0.9% during the third quarter. Swedbank AB now owns 3,139,552 shares of the biopharmaceutical company’s stock worth $162,440,000 after purchasing an additional 28,427 shares in the last quarter. Cyndeo Wealth Partners LLC boosted its position in shares of Bristol-Myers Squibb by 3.9% during the third quarter. Cyndeo Wealth Partners LLC now owns 9,535 shares of the biopharmaceutical company’s stock worth $493,000 after purchasing an additional 357 shares in the last quarter. Vest Financial LLC bought a new position in shares of Bristol-Myers Squibb during the third quarter worth $438,000. Finally, Raleigh Capital Management Inc. boosted its position in shares of Bristol-Myers Squibb by 42.7% during the third quarter. Raleigh Capital Management Inc. now owns 42,480 shares of the biopharmaceutical company’s stock worth $2,198,000 after purchasing an additional 12,705 shares in the last quarter. 76.41% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of equities analysts have recently weighed in on BMY shares. Cantor Fitzgerald lifted their price target on shares of Bristol-Myers Squibb from $50.00 to $55.00 and gave the stock a “neutral” rating in a research report on Tuesday, February 4th. Wolfe Research assumed coverage on shares of Bristol-Myers Squibb in a research report on Friday, November 15th. They set a “peer perform” rating on the stock. Bank of America reaffirmed a “neutral” rating and issued a $63.00 price objective on shares of Bristol-Myers Squibb in a research report on Tuesday, December 10th. Wells Fargo & Company boosted their price objective on shares of Bristol-Myers Squibb from $60.00 to $62.00 and gave the company an “equal weight” rating in a research report on Friday, February 7th. Finally, BMO Capital Markets boosted their price objective on shares of Bristol-Myers Squibb from $57.00 to $61.00 and gave the company a “market perform” rating in a research report on Tuesday, November 12th. Two equities research analysts have rated the stock with a sell rating, twelve have issued a hold rating, four have assigned a buy rating and three have issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $57.86.

Bristol-Myers Squibb Stock Up 1.0 %

BMY opened at $54.45 on Wednesday. The company has a debt-to-equity ratio of 2.83, a current ratio of 1.24 and a quick ratio of 1.09. The company’s 50-day moving average is $57.04 and its 200 day moving average is $54.23. Bristol-Myers Squibb has a fifty-two week low of $39.35 and a fifty-two week high of $61.10. The firm has a market capitalization of $110.49 billion, a P/E ratio of -12.32, a PEG ratio of 2.13 and a beta of 0.45.

Bristol-Myers Squibb (NYSE:BMY) last posted its quarterly earnings data on Thursday, February 6th. The biopharmaceutical company reported $1.67 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.47 by $0.20. Bristol-Myers Squibb had a negative net margin of 18.53% and a positive return on equity of 13.81%. Research analysts expect that Bristol-Myers Squibb will post 6.75 earnings per share for the current fiscal year.

Bristol-Myers Squibb Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Monday, February 3rd. Investors of record on Friday, January 3rd were issued a dividend of $0.62 per share. This represents a $2.48 dividend on an annualized basis and a yield of 4.56%. The ex-dividend date of this dividend was Friday, January 3rd. This is an increase from Bristol-Myers Squibb’s previous quarterly dividend of $0.60. Bristol-Myers Squibb’s dividend payout ratio (DPR) is -56.11%.

About Bristol-Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.